MP CARDIOFLOW-B(02160): Eno series pacemaker receives CE approval for LBBAP indication.

MP CARDIOFLOW-B (02160) announcement: Recently, the ENO series of cardiac pacemakers developed independently by our group have obtained CE approval for Left Bundle Branch Area Pacing (LBBAP). With this, all six CE-certified pacemakers of our group have been approved for LBBAP indication. With the commercialization of the FLEXIGO 3D LBBAP delivery system and VegaTM M58 electrode lead, our group now has a complete solution for LBBAP therapy, which can meet the clinical needs of more patients and further expand revenue sources. LBBAP therapy is an advanced physiological pacing technology internationally, which accurately implants electrodes in the left bundle branch and its adjacent areas to conduct electrical signals along the heart's natural conduction system, achieving synchronous contraction of the left and right ventricles and significantly improving cardiac pumping efficiency. This therapy is closer to physiological pacing, effectively reducing the risk of heart failure due to long-term ventricular dyssynchrony, suitable for patients with bradycardia, conduction block, etc., significantly improving patient quality of life and long-term prognosis. It is an important upgrade and alternative to traditional right ventricular pacing and biventricular pacing, receiving clear recommendations in guidelines both domestically and internationally, with its clinical status rapidly rising. Looking ahead, our group will leverage over 60 years of expertise in arrhythmia management, deep integration of structural heart disease business with technical advantages in active implantable devices, remote monitoring, sensor algorithms, passive intervention, delivery systems, valve design, biomaterials, hemodynamics monitoring, accelerating innovation research and development in heart failure field and global commercialization, aiming to provide innovative comprehensive device management solutions covering all causes, stages, and processes of heart failure for global patients, benefiting them with higher quality and more accessible innovative therapies.